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Abstract: Metastatic colorectal cancer (mCRC), like many cancers, is primarily a disease of 
elderly people. Despite this prevalence, such patients are often excluded from randomized tri-
als or represent a minority of enrolled patients. Moreover, the criteria for establishing benefit 
or side effects of treatment strategies in this population are uncertain and not well recognized. 
Bevacizumab improves the outcome of mCRC when used in combination with standard first-
line and second-line chemotherapy and beyond the first disease progression when given with a 
chemotherapy backbone different from that used in the precedent line. The particular toxicity 
profile of this antiangiogenesis agent (in particular hypertension, thromboembolic events, hem-
orrhage, and renal failure) may discourage its use in elderly patients with comorbidities. Data 
from subgroup analyses of randomized trials and the results of recent cohort studies suggest 
a significant benefit from the addition of bevacizumab to standard chemotherapy for elderly 
patients comparable with that observed in younger patients, except for the increased risk for 
thromboembolic events. Age alone should not be a barrier to use of bevacizumab, and further 
research with a more complete geriatric assessment should investigate the role of bevacizumab 
in elderly patients with mCRC to avoid undertreatment of this patient population due to a 
 historical conservative approach.
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Introduction
Colorectal cancer (CRC) is the third leading cause of cancer-specific death in 
females and the fourth in males worldwide.1 The incidence and mortality of CRC 
increases with advancing age, and the global burden of the disease is expected to 
grow further over the next few decades due to the increase in life expectancy.2 In 
the USA, approximately 60% of new cases of CRC and 70% of CRC-related deaths 
occur in patients aged 65 years and older.3 About 50% of patients diagnosed with 
early-stage disease will ultimately develop metastatic CRC (mCRC) in spite of radi-
cal surgery and adjuvant therapies, whereas 25% of patients present with de novo 
mCRC at diagnosis. Unfortunately, when metastatic disease occurs, the prognosis 
remains poor, even if survival has improved, often exceeding 24 months, due to the 
introduction of targeted agents.4
Despite the high prevalence of the disease in the elderly, this patient population 
has been historically excluded or underrepresented in most clinical trials because of 
stringent inclusion criteria. Moreover, elderly patients enrolled in trials are highly 
selected, and generally fitter than the average patients observed in daily clinical 
practice. As a result, there is not sufficient evidence on the appropriate management 
of elderly patients with mCRC. The safety and efficacy of standard chemotherapy in 
older patients seem to be comparable with that reported for younger individuals,5 but 
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limited data are available about the tolerance and effective-
ness of biologic agents in the elderly population.
Bevacizumab (Avastin®, Genentech, South San 
Francisco, CA, USA) is a recombinant, humanized mono-
clonal antibody that specifically targets vascular endothelial 
growth factor.6 Bevacizumab improves progression-free 
survival (PFS) and overall survival (OS) of mCRC patients 
when added to chemotherapy in the first-line and second-line 
setting and beyond the first disease progression when given 
with a chemotherapy backbone different from that used in 
the front line.7–9 Bevacizumab has a particular toxicity pro-
file including: cardiovascular events, such as hypertensive 
crisis, chronic heart failure, myocardial infarction, venous 
thromboembolic events, and arterial thrombotic events; 
cerebrovascular events, such as transient ischemic attack, 
stroke, and central nervous system hemorrhage; gastro-
intestinal perforation; fistula formation; wound healing 
complications; and nephrotic syndrome.10,11 These adverse 
events may be of some concern for medical oncologists when 
choosing treatment for elderly patients with mCRC, and an 
accurate risk-benefit balance should be carried out before 
planning the therapeutic strategy on an individual basis. The 
aim of this paper is to present the available evidence on the 
efficacy and safety of bevacizumab in elderly patients with 
mCRC, in order to help clinicians select patients who are 
potentially good candidates for receiving a bevacizumab-
based therapy.
Literature search methodology
The currently available evidence on the effectiveness and 
tolerability of bevacizumab in older patients derives from 
retrospective analyses of subgroups enrolled in clinical trials 
without an upper age limit, pooled analyses of randomized 
trials, observational community-based studies, and prospec-
tive, randomized clinical trials specifically assessing the 
efficacy and safety of bevacizumab in elderly patients. For 
this paper, the PubMed database was searched for papers 
published before January 2014 using “bevacizumab” AND 
“colorectal cancer” AND “elderly” as search terms.
Subgroup analyses of randomized 
clinical trials
In the AVF2107g study, a landmark, randomized, placebo-
controlled, Phase III clinical trial, the addition of bevacizumab 
to an irinotecan-based chemotherapy as first-line treatment for 
mCRC significantly improved OS (20.3 versus 15.6 months, 
hazard ratio [HR] 0.66), PFS (10.6 versus 6.2 months, 
HR 0.54) and response rate (44.8% versus 34.8%).7 Subgroup 
data analysis suggested a comparable survival benefit (HR 
0.61) for patients aged 65 years, who represented 32% 
of the entire population enrolled in the study. In this trial, 
bevacizumab did not exacerbate chemotherapy-related toxici-
ties, but was associated with an increased incidence of grade 
three hypertension (11% versus 2.3%) and gastrointestinal 
perforation (1.5% versus 0%). The incidence and grade of 
bevacizumab-related adverse events were not reported by age 
group, and concerns remained regarding the safety profile of 
bevacizumab in elderly patients.7
More information on the tolerability of bevacizumab in 
older patients was provided by the randomized, double-blind 
Phase II AVF2192g study evaluating the addition of beva-
cizumab to fluorouracil/leucovorin in patients with a poor 
prognosis and deemed unfit for first-line irinotecan-based 
chemotherapy.12 The design of this study was based on a 
retrospective, exploratory analysis of a small randomized 
Phase II trial (AVF0780)13 comparing 5-fluorouracil/folinic 
acid alone or combined with two different bevacizumab doses 
(5 or 10 mg/kg), which suggested a particularly meaning-
ful clinical benefit from anti-vascular endothelial growth 
factor therapy in a subset of patients with poor prognostic 
features, including age 65 years, Eastern Coast Oncology 
Group performance status  1, and albumin 3.5 g/dL.13 
As a result of the eligibility criteria used for the AVF2192g 
trial, 80% of patients were aged 65 years, and the mean 
age was 70.7 and 71.3 years in the fluorouracil-leucovorin 
arm and fluorouracil-leucovorin plus bevacizumab arm, 
respectively.12 Patients receiving bevacizumab had a sig-
nificantly longer median PFS (9.2 versus 5.5 months; HR 
0.5; P=0.0002),12 but the study did not meet the primary 
endpoint of demonstrating a 39% reduction in risk of death 
in the bevacizumab arm. However, the median OS was 
3.7 months longer for patients treated with bevacizumab 
and chemotherapy in comparison with those who received 
chemotherapy plus placebo (16.6 versus 12.2 months; HR 
0.79; P=0.16).12 Despite its use in a population at high risk 
for serious adverse events, bevacizumab was well tolerated. 
Grade three hypertension was more frequent with beva-
cizumab (16% versus 3%) but was manageable with anti-
hypertensive drugs, and did not lead to any discontinuation 
of treatment. There was no difference between the two groups 
in terms of incidence of bleeding and venous thromboembolic 
events, but an increased rate of arterial thrombotic events was 
observed in the bevacizumab arm when compared with the 
placebo arm (10% versus 4.8%).12
Further information on use of bevacizumab in the 
elderly population derives from subgroup analyses of 
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other randomized studies in patients not selected for age. 
In the Phase III BICC-C (Bolus Infusional, or Capecitabine 
with Camptostar-Celecoxib) study, 430 mCRC patients 
were randomized to receive first-line FOLFIRI, modified 
irinotecan/fluorouracil/levoleucovorin (mIFL), or irinotecan 
plus capecitabine.14 After approval of bevacizumab, the 
study protocol was amended and an additional 117 patients, 
24.8% of whom were elderly, were randomized to FOLFIRI 
or mIFL plus bevacizumab. The subgroup analysis did not 
show any significant difference in terms of efficacy and safety 
of bevacizumab plus chemotherapy for patients 65 years 
compared with those 65 years.14
The randomized Phase III CAIRO-2 study (ClinicalTri-
als.gov identifier NCT00208546) investigated the addition 
of the anti-epidermal growth factor receptor monoclonal 
antibody cetuximab to bevacizumab plus capecitabine 
and oxaliplatin (CAPOX) in previously untreated mCRC 
patients.15 The study reported negative results, since the 
combination of the two monoclonal antibodies with chemo-
therapy determined a shorter PFS and a poorer quality of life. 
A subgroup analysis performed in the control arm showed 
that the effect of bevacizumab plus CAPOX was similar in 
terms of median PFS across ages (10.6 versus 9.6 versus 
13.5 months for patients aged 75, 70–75, and 75 years, 
respectively; P=0.908), but a trend toward a worse median 
OS was observed in elderly patients (20.3 versus 17.6 versus 
13.1 months for patients aged 75, 70–75, and 75 years, 
respectively; P=0.063).16 The incidence of grade three and 
four adverse events did not differ significantly among the 
three age groups. However, older patients discontinued treat-
ment for unacceptable toxicity more frequently than younger 
patients, and it is not clear whether bevacizumab was the 
main reason responsible for early discontinuation in elderly 
patients, since the evaluation of bevacizumab-specific tox-
icity among the three age groups was not an object of the 
analysis.16 The Australasian Gastrointestinal Trials Group 
MAX study was a Phase II/III trial comparing capecitabine 
versus capecitabine plus bevacizumab versus capecitabine 
and mitomycin plus bevacizumab as first-line therapy for 
mCRC patients.17 The addition of bevacizumab to chemo-
therapy resulted in an improved PFS in comparison with 
capecitabine alone (5.7 months for capecitabine, 8.5 months 
for capecitabine and bevacizumab, and 8.4 months for 
capecitabine, mitomycin and bevacizumab; capecitabine 
versus capecitabine plus bevacizumab, HR 0.63; P0.001). 
Patients aged 75 years, who comprised 21% of the overall 
population enrolled in the study, achieved a comparable 
benefit in terms of PFS when treated with bevacizumab 
(HR 0.53 for capecitabine versus capecitabine plus beva-
cizumab; P=0.001).18 The effect of bevacizumab was not 
different between patients 75 and 75 years, as suggested 
by an interaction test between treatment and age groups for 
response rate, PFS, and OS. Interestingly, no significant dif-
ferences in bevacizumab-related toxicity were reported by 
age. However, in elderly patients receiving bevacizumab and 
chemotherapy, an increased rate of hand-foot syndrome was 
observed, and this finding may reflect the longer exposure 
to treatment in the bevacizumab-containing arm.18
Pooled analyses from prospective 
trials
Subgroup data analyses for age are limited to the small num-
ber of elderly patients enrolled in each trial, and generally 
lack the power to detect any significant difference in outcome 
between younger and older patients. Pooling data from 
different studies increases the sample size for the analysis, 
producing more reliable results.
A pooled analysis of data from the AVF2107g and 
AVF2192g studies included 439 patients aged 65 years 
(276 patients 70 years), and showed that bevacizumab 
was associated with a statistically significant and clinically 
meaningful improvement in median PFS (9.2 versus 
6.2 months; HR 0.52; P0.0001) and OS (19.3 versus 
14.3 months; HR 0.70; P=0.006) in this elderly population, with 
a similar benefit observed also for patients aged 70 years.19 
The incidence of bevacizumab-associated adverse events was 
comparable with that observed in the overall study popula-
tions in the two trials, and did not result in a higher rate of 
treatment discontinuation.
Cassidy et al20 pooled data from the AVF2107g and 
AVF2192g trials with data from two randomized Phase III 
studies of oxaliplatin-based chemotherapy with or with-
out bevacizumab in the first-line and second-line setting, 
respectively, ie, the NO16966 trial and the E3200 trial. In 
this analysis, data from 1,142 patients aged 65 years and 
712 patients 70 years were compared with those from 
1,864 patients 65 years. This analysis confirmed a remark-
able survival advantage for older patients from the addition 
of bevacizumab to standard chemotherapy in comparison 
with chemotherapy alone. Indeed, bevacizumab prolonged 
median PFS from 6.7, 6.9, and 6.4 months to 9.5 (HR 0.59; 
P0.0001), 9.3 (HR 0.58; P0.0001), and 9.2 months 
(HR 0.54; P0.0001), and median OS from 16.5, 15, and 
14.1 months to 19.9 (HR 0.77; P0.0001), 17.9 (HR 0.85; 
P=0.015), and 17.4 months (0.79; P=0.005) for patients 
aged 65, 65, and 70 years, respectively.20 As shown 
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by the difference among HRs for progression and for death 
(Table 1), the effect of bevacizumab on median OS was less 
pronounced than its effect on median PFS. Regarding the 
safety profile of bevacizumab, the pooled analysis revealed 
that most of the bevacizumab-associated adverse events in 
the elderly population were not more frequent than those 
observed in younger patients. However, the incidence of arte-
rial thrombotic events was higher in elderly patients receiving 
bevacizumab than in those treated with chemotherapy alone 
(5.7% versus 2.5% for patients 65 years, 6.7% versus 3.2% 
for patients 70 years).20
Data from randomized prospective 
clinical trials in geriatric populations
AVEX (AVastin in the Elderly with Xeloda) was the first 
trial evaluating the efficacy and safety of the addition of 
bevacizumab to chemotherapy specifically in an elderly 
population (Table 1).21 In this open-label Phase III study, 
280 patients aged 70 years with previously untreated 
mCRC and deemed not candidates for oxaliplatin-based or 
irinotecan-based chemotherapy were randomized to receive 
capecitabine alone or capecitabine with bevacizumab. 
Patients were excluded from the study if they had clinically 
significant cardiovascular disease or a history of thromboem-
bolic events within the previous 6 months. The median age 
was 77 years in the control group and 76 years in the beva-
cizumab group, and about 50% of patients had an Eastern 
Coast Oncology Group performance status  1. The response 
rate and disease control rate were significantly higher in the 
combination arm (19.3% versus 10%, respectively, P=0.042; 
and 74.3% versus 57.9%, P=0.005).21 Moreover, the addi-
tion of bevacizumab to capecitabine led to a 4-month gain 
in median PFS (9.1 versus 5.1 months; HR 0.53; P0.001), 
which was the primary endpoint of the study. The effect of 
bevacizumab on PFS was consistent across all age groups, 
with HRs of 0.52, 0.60, and 0.36 for patients aged 70–74, 
75–79, and 80 years, respectively. OS was longer for the 
bevacizumab arm compared with the capecitabine alone arm 
(20.7 versus 16.8 months), although the difference was not 
statistically significant.21 However, as the authors pointed 
out, the study was not powered to detect differences in OS. 
Treatment-related toxicities of grade three occurred more 
frequently in the bevacizumab-containing arm than in the 
control group (40% and 22%, respectively), and treatment 
discontinuation because of adverse events was more com-
mon for patients treated with bevacizumab and capecitabine 
compared with those receiving capecitabine alone (41% 
versus 26%). Furthermore, venous thromboembolic events 
and hand-foot syndrome were more frequent in the combina-
tion arm than in the capecitabine arm. However, the overall 
incidence of thromboembolic events was not different from 
that reported for nonelderly patients in previous trials with 
bevacizumab.
Data from observational 
community-based trials
Patients enrolled in clinical trials represent a highly selected 
population. They are often fit and without relevant comor-
bidities, and are different from the general population of 
elderly patients managed in daily clinical practice, who often 
have poorer performance status and additional risk factors. 
Observational studies provide an interesting opportunity to 
evaluate the efficacy and safety of bevacizumab in older 
patients outside of the clinical trials setting. 
BRiTE (Bevacizumab Regimens: Investigation of 
Treatment Effects and Safety) was a prospective, observational 
study evaluating the efficacy and tolerability of bevacizumab 
and chemotherapy in a community-based setting.22 A sub-
group analysis for age groups in this study showed that 
median PFS times were 9.6, 10, and 8.6 months for patients 
Table 1 Main studies of the effectiveness of adding bevacizumab to standard chemotherapy in elderly patients with metastatic colorectal 
cancer 
Reference N % Backbone CT Line RR % PFS (months) OS (months)
Kabbinavar et al20 139 CT/B
137 CT
IFL/FL 1 30.9 vs 25.5 
NS
9.2 vs 6.2
HR 0.51
P0.0001
18.7 vs 12.6
HR 0.69
P=0.015
Cassidy et al21 362 CT/B
350 CT
IFL/FL/
XELOX/
FOLFOX
1/2 NA 9.2 vs 6.4
HR0.54
P0.0001
17.4 vs 14.1
HR 0.79
P=0.005
Cunningham et al22 140 CT/B
140 CT
Capecitabine 1 19.3 vs 10.0
P=0.04
9.1 vs 5.1
HR 0.53
P0.001
20.7 vs 16.8
HR 0.79
P=0.18
Abbreviations: CT, chemotherapy; B, bevacizumab; RR, response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NA, not applicable; 
IFL, irinotecan/fluorouracil/levoleucovorin; FL, fluorouracil/levoleucovorin; XELOX, capecitabine/oxaliplatin; FOLFOX, 5-fluorouracil/leucovorin/oxaliplatin.
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aged 65–74, 75–80, and 80 years, comparable with the 
median PFS observed in younger patients (9.8 months).23 
In contrast, the median OS decreased with age, from 26 months 
for patients 65 years to 16.2 months in patients 80 years. 
However, elderly patients receive all the active drugs for 
mCRC less frequently than younger patients, and it has been 
demonstrated that median OS is longer with exposure to all 
effective therapies.24 The safety profile of bevacizumab in the 
BRiTE study was similar for older and younger patients, with 
the exception of thromboembolic events, which increased 
significantly with age, occurring in 1.4% of patients aged 
65 years, 4% of those aged 75–80 years, and 4% of those 
aged 80 years.23 In the prospective, observational ARIES 
(Avastin Registry: Investigation of Effectiveness and 
Safety)25 study, there was no difference between patients 
aged 70 years and 70 years in terms of PFS both in 
first line (10.3 versus 9.9 months; HR 1.11) and second line 
(7.9 versus 7.9 months; HR 0.96). However, in this study, 
for patients receiving bevacizumab in first line, median OS 
was longer for younger patients (25.1 versus 19.6 months, 
HR 1.23).25
A cohort of 2,526 mCRC patients aged 65 years treated 
from 2002 to 2007 with a fluoropyrimidine-based chemo-
therapy regimen as first line was identified by Meyerhardt 
et al within the Surveillance, Epidemiology and End Results 
(SEER) Medicare database.26 All the patients received a 
fluoropyrimidine-based chemotherapy regimen as first line. 
Addition of bevacizumab in 903 of these patients significantly 
prolonged median OS (19 versus 15.9 months; HR 0.87; 
P=0.003), but the benefit was limited to patients receiving 
irinotecan. Interestingly, patients treated with chemotherapy 
alone and those treated with chemotherapy and bevacizumab 
experienced a comparable rate of thromboembolic events 
within the first 6 months of treatment (17.1% and 16.4%), 
and the rate of cardiac events was higher in the chemotherapy 
group than in the bevacizumab group (14.5% versus 11.5%). 
However, stroke occurred more frequently in patients receiv-
ing bevacizumab (4.9% versus 2.5%).26 The SEER database 
was also searched by Shankaran et al27 who analyzed data 
from patients aged 65 years and diagnosed with mCRC 
between 2001 and 2007. Of 6,821 patients, 3,282 (48%) were 
diagnosed in 2005–2007, and 19% of them received first-line 
bevacizumab. In contrast with other reports, adverse event 
incidence rates in this analysis were comparable between 
patients in 2001–2003 receiving first-line chemotherapy (135 
events per 100,000 person-days) and patients in 2005–2007 
receiving first-line chemotherapy with bevacizumab (141 
events per 100,000 person-days).
Specific issues in the treatment 
of geriatric patients
The optimal management of elderly patients with mCRC is 
still challenging. Assessment of geriatric patients consid-
ering only the “chronological age” may be inadequate to 
make a decision on the treatment strategy. Indeed, patients 
in the same age groups are often heterogeneous with respect 
to overall health status. Geriatric medicine has developed 
specific tools to detect some issues that can be missed by 
routine clinical and physical examination. A comprehensive 
geriatric assessment (CGA) includes social parameters, func-
tional status and falls history, cognitive and psychological 
status, nutritional status, comorbidities, and polypharmacy.28 
In elderly patients with cancer, several domains of CGA 
were demonstrated to correlate with oncological outcomes. 
Therefore, multiple organizations, including the Interna-
tional Society of Geriatric Oncology,29 have recommended 
that all older patients should undergo a CGA at the time of 
diagnosis and in the decision-making process. However, a 
CGA might be resource-consuming and time-consuming in 
daily practice, and rapid screening tests have been developed 
for a brief geriatric evaluation.30 Although CGA and rapid 
screening tests are prognostic tools, they have not been 
widely used in clinical trials as inclusion or stratification 
criteria. Also, in the AVEX trial, the only available Phase III 
study of bevacizumab in elderly patients, formal geriat-
ric and comorbidity assessments were not performed.21 
Another important issue when treating elderly patients with 
mCRC, given the palliative intent of the therapy, is quality 
of life (QoL). Only limited data are available on the effect 
of bevacizumab on QoL in older patients. In the subgroup 
analysis of the CAIRO-2 study, QoL was not significantly 
different across age groups of patients treated with CAPOX 
plus bevacizumab; in this study, a 10-point increase in QoL 
was achieved in 17%, 15%, and 33% of patients aged 75, 
70–75, and 75 years, respectively.16
Conclusion
Data from retrospective subgroup analyses and pooled analy-
ses of randomized clinical trials, taken together with results 
from observational cohort studies, suggest a meaningful 
benefit from the addition of bevacizumab to standard 
chemotherapy for elderly patients with mCRC (Table 1).31 
The effectiveness of bevacizumab in older patients was 
comparable with that observed in younger patients. Recently, 
results from the AVEX trial confirmed a significant improve-
ment of median PFS with the addition of bevacizumab to 
capecitabine.21 Bevacizumab is well tolerated, but its use 
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may increase the risk of thromboembolic events, and the 
AVEX and the Australasian Gastrointestinal Trials Group 
MAX studies showed that it can also exacerbate hand-foot 
syndrome when given with capecitabine.18,21 Therefore, age 
alone should not be a barrier to use of bevacizumab, but treat-
ment should be individualized, carefully selecting patients 
on the basis of medical history, with adequate assessment 
of clinically relevant comorbidities or risk factors, such 
as recent cardiovascular events, uncontrolled hyperten-
sion, or unstable angina. Furthermore, during treatment 
with bevacizumab, particular attention should be paid to 
monitoring and treating side effects in order to optimize the 
risk-benefit ratio. When patients are not properly selected, 
toxicity related to bevacizumab may be potentially more than 
expected. It should also be kept in mind that elderly patients 
treated outside of clinical trials are often frail, and that pres-
ervation of QoL is crucial in this setting. Further research 
should investigate the role of bevacizumab in elderly mCRC 
patients, with the incorporation of CGA, QoL assessment, 
and geriatric endpoints in clinical trials.
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